The alliance with Medable enables Covance to expand its decentralised clinical trials technology ecosystem. Credit: National Cancer Institute on Unsplash

US-based life sciences firm LabCorp has announced that Covance, its drug development business, is bolstering its technology ecosystem to speed up the adoption of decentralised clinical trials.

Through an alliance with software provider for digital clinical trials Medable, Covance is expanding its decentralised clinical trials technology ecosystem.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The Covance patient and site interface will be powered by Medable’s modular software platform. This will offer immediate access to applications, which will enable patients to take part in decentralised clinical trials.

Furthermore, the platform will allow data and system interoperability, aid in remote data collection and engagement between sites, patients, and clinical investigators.

Covance Enterprise Solutions president Bill Hanlon said: “Working together, we can apply the full capabilities of LabCorp Diagnostics business, Covance, and our technology ecosystem to extend patient access, improve the patient experience, and accelerate timelines for clinical development.

“We will continue to play a critical role as aggregators and integrators to provide customers with the access, flexibility, and scale necessary to enable global decentralised studies, and to rapidly innovate in ways that improve the patient experience and trial efficiency.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

According to Medable, the firms are creating the first data-driven, decentralised trial ecosystem with this partnership.

Medable co-founder and CEO Michelle Longmire said: “Working with LabCorp Diagnostics and Covance allows us to deepen patient engagement and reduce burden for trial participants, and this decentralised trial ecosystem will help us get effective therapies to patients faster. This innovative ecosystem will accelerate trial timelines.”

Last year, Covance launched a solution to transform the conduct of decentralised clinical trials.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact